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Abstract
Purpose The reasons for the dramatic increase in proton
pump inhibitors (PPI) prescriptions remain unclear and
cannot be explained solely by increased morbidity, new
indications or a decrease in alternative medication. Inap-
propriate use and discharge recommendations in hospitals
are considered to be possible explanations. As the quality of
PPI recommendations in hospital discharge letters in
Germany has not been investigated to date, we have studied
the appropriateness of these referrals.
Methods Hospital discharge letters with recommendations
for PPI medication from 35 primary care practices in the
county of Mecklenburg-Western Pomerania (MV; North-
east Germany) were collected and analysed, and the
appropriateness of the PPI indication was rated.
Results No information justifying the recommendation for
continuous PPI medication could be identified in 54.5% of
the discharge letters; in 12.7%, the indication was uncer-
tain, and in 32.7%, we found an evidence-based indication
for PPI medication. The most common indication for
adequate PPI use was nonsteroidal anti-inflammatory
drug-prophylaxis in high-risk patients.
Conclusions Inadequate recommendations for PPIs in
discharge letters are frequent. This may lead to a continu-
ation of this therapy in primary care, thereby unnecessarily
increasing polypharmacy and the risk of adverse events as
well as burdening the public health budget. Hospitals
should therefore critically review recommendations for
PPI medication and the dosage thereof in their discharge
letters and clearly document the reason for PPI use and the
need for continuous prescription in primary care.
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Introduction
Proton pump inhibitors (PPIs) are the most potent medi-
cations currently available to reduce gastric acid secretion.
Their use is widespread and on the increase, with annual
sales worldwide that have surpassed US $25 billion. The
prescribing of PPIs in Germany rose from 44 million
defined daily doses (DDD) in 1993 to 1,674 million DDD
in 2008 (+3,805%), with an associated cost of 540 million
Euros per year. The reasons for this are unclear and cannot
be explained solely by increased morbidity, new indications
[1] or a decrease in alternative medication.
PPIs are indicated for the treatment of gastro-
oesophageal reflux disease (GERD) [2], peptic ulcer [3]
and, in combination with two suitable antibiotics, for the
eradication of Helicobacter pylori infection. After eradica-
tion, continuation of PPI medication is not necessary [4].
PPIs also are recommended to prevent nonsteroidal anti-
inflammatory drug (NSAID)- and aspirin-induced ulcers in
high-risk patients [5–7] (Table 1) and for the treatment of
gastritis. In intensive care, PPIs are indicated for stress ulcer
prophylaxis in patients with a risk of bleeding [8]. The use
of PPI for patients with Barrett–Oesophagus is controver-
sial, and its role, if any, in the prevention of carcinoma
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DOI 10.1007/s00228-010-0871-9induction has not yet been demonstrated [9]. A Cochrane
Review reported that PPIs could be effective in a small
proportion of patients with dyspepsia, but studies have
shown a significant heterogeneity. Some guidelines recom-
mend testing for H. pylori and eradication if necessary,
others suggest an empirical PPI treatment 4–8 weeks as an
alternative treatment [10]. Also, there is no clear evidence
to support the assumption that PPIs prevent bleeding and
promote quicker healing after ligation in patients with liver
cirrhosis and oesophageal varices [11]. Some authors
recommend ulcer prophylaxis for patients on a combination
of aspirin and clopidogrel [12], but there has been some
concerns about the interaction of clopidogrel and PPIs
reducing cardiovascular protection and increasing arterio-
sclerotic complications [13, 14].
The prescription of PPIs without clear indications has
been frequently observed in many countries in hospitals
[15–19] and primary care [20] alike. Reported rates of non-
indicated prescriptions on general medical wards range
from 40 to 81% [15–19], while inadequate acid-suppressive
medication is often continued after discharge for long time
[19, 21].
Although PPIs are generally considered safe, it has been
shown that long-term use might be associated with hip
fractures [22, 23], pseudomembranous colitis [24]a n d
respiratory infections, such as pneumonia [25]. In addition,
the cost of unnecessary medication burdens the national
health budget.
The aim of this study was to analyse the appropriateness
of PPI treatment recommendations in patients discharged
from hospital in a large German county.
Methods
This cross-sectional observational study was conducted in
35 primary care practices in the state of Mecklenburg-
Vorpommern (MV), North-Eastern Germany.
Recruitment of practices We invited all 933 registered
general practitioner (GP) practices in MV to participate in
the study. Addresses were obtained from the Association of
Statutory Health Insurance Physicians (Kassenaerztliche
Vereinigung). A total of 97 GPs agreed to participate the
study, respresenting 35 practices (Fig. 1) The sample was
stratified by area: two practices from each of 12 rural
districts and six major towns in MV were randomly selected.
Identification of patients Patients included in this study
were members of the AOK (Allgemeine Ortskrankenkasse)
Table 1 Rating of indications for proton pump inhibitors
Indications for proton pump inhibitors
Indications rated as adequate
Gastroesophageal reflux disease [2]
Treatment and recurrent prophylaxis of peptic ulcer [3, 37]
Eradication of Helicobacter pylori [4]
Pathologic hypersecretory conditions (e.g. Zollinger–Ellison syndrome) [38]
Histological proven diagnosis of gastritis [31, 32]
Prevention of medication-induced ulcers: [5–7]
-NSAID at patients >65 years
-NSAID and corticosteroid
-NSAID and warfarin /coumadin
-NSAID and patient history of ulcer/ GI bleeding
-Aspirin and corticosteroid
-Aspirin and warfarin/coumadin
-Aspirin and NSAID
Indications rated as uncertain
Dyspepsia
Barrett–Oesophagus [9]
Oesophageal varices [10, 11]
Ulcer prophylaxis with clopidogrel and low dose aspirin [13, 14]
Patient underwent upper gastrointestinal endoscopy and biopsy, result outstanding at discharge [31, 32]
History of gastritis, no endoscopy, no further information
Anaemia, no endoscopy
NSAID, Nonsteroidal anti-inflammatory drug
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covering 27% of the population in MV. All patients from
the participating practices >18 years of age discharged from
hospital between 1 July 2006 and 30 June 2007 were
identified from insurance records. In patients with multiple
hospital admission, only the first discharge was included.
Patients who have received intensive care treatment were
excluded.
Data collection Practice nurses received an instruction
folder containing the names of all PPI preparations
available in Germany. They were asked to screen discharge
letters of all the patients identified for PPIs in the discharge
medication. Letters recommending PPIs were copied,
anonymized and sent to the study centre.
Two raters (DA and GB) assessed all clinical informa-
tion available in the discharge letter (including co-
medication) justifying a recommendation for continuous
treatment with PPIs. The indication was rated as adequate,
inadequate or uncertain (Table 1). Adequate use of a PPI
was defined on the basis of approved indications (as written
in the official product information) and indications sup-
ported by clinical guidelines and scientific literature. If the
PPI recommendation was rated as inadequate, we analysed
the discharge letter to assess what may have triggered the
decision. Differences in judgment between the authors were
resolved by discussion.
The study was approved by the Ethics Committee of the
medical school of the University of Göttingen.
Statistical analysis Simple descriptive statistics were
used. To explore factors associated with inadequate
recommendation of PPI, we conducted univariate analy-
ses comparing patients who received an adequate PPI
recommendation with those who did not. In a second
step, we performed logistic regression analysis to
calculate the probability of receiving an inadequate PPI
recommendation. We excluded patients with an uncertain
indication from the regression model. Covariates retained
in the final model were selected with the score
procedure. Goodness of fit was assessed with the Hosmer
Lemshow test. The software package SAS 9.2 (SAS,
Cary, NC) was used for the analysis.
Results
In the participating practices, a total of 2,951 patients
discharged from hospitals were identified in the respective
time period. Practice nurses identified 681 (23%) hospital
discharge letters containing a recommendation for PPIs. The
patient flow is shown in Fig. 1. Of the participating patients,
382 (57%) were female, and the mean age (± standard
deviation) was 70.7 (±13.7) years. Demographic data on the
patient cohort and co-medications used by these patients
discharged with PPI are shown in Table 2. H. pylori testing
was performed in 96 (14.2%) of 209 patients who had a
documented upper gastrointestinal endoscopy, of whom 44
tested positive. Seventeen patients had no pathologic find-
ings on endoscopy and did not take any ulcer-inducing
medication.
No information justifying the recommendation for
continuous PPI medication could be identified in 371
(54.5%) of all discharge letters; in 12.7%, the indication
was uncertain, and in 32.7%, we found an evidence-based
indication for PPI medication. The most common indication
for adequate PPI use was NSAID-prophylaxis in high-risk
patients, followed by endoscopically proven gastritis. In
patients without an adequate indication, the most common
“finding” in the discharge letter was that there was no
reason given for the continuous prescription of the PPI; the
next most common reason was ulcer prophylaxis in patients
taking low-dose aspirin alone (Table 3).
2951 discharge letters from 
35 practices: scanned for 
PPI in discharge medication 
729 patients from            
35 practices: 
discharge letters with PPI  
1038 discharge letters: 
not found in practices 
48 discharge letters: 
incomplete
681 patients from 35 
practices included 
36 practices included 
1 practice dropped out 
3989 hospitalized patients 
from 35 practices (insurance 
records) 
Fig. 1 Patient flow. PPI Proton pump inhibitor
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lower risk of inadequate recommendation for PPIs were
endoscopy [odds ratio (OR) 0.18, 95% confidence interval
(CI) 0.12–0.16], testing for H. pylori (OR 0.1, 95% CI 0.06–
0.18), NSAID (OR 0.15, 95% CI 0.08–0.25) or oral
anticoagulation (OR 0.4, 95% CI 0.22–0.69). No association
was found with age, gender, polypharmacy (defined as >5
concomitant medications) and hospital type (Table 2). After
adjustment with multivariate analysis, endoscopy (OR 0.13,
95% CI 0.08–0.22), testing for H. pylori (OR 0.1, 95% CI
0.06–0.18), co-medication of NSAIDs (OR 0.14, 95% CI
0.09–0.21) or oral anticoagulation (OR 0.24, 95% CI 0.12–
0.49) remained significant factors that decreased the risk of
inadequate PPI recommendation (R
2 0.48).
The most commonly prescribed PPI was pantoprazole (n=
487, 72%). Recommended daily doses are shown in Table 4.
Discussion
Our study confirms that PPIs in hospitals are often
prescribed without a clear indication. In 54.5% of the
discharge letters recommending PPIs analysed, no appro-
priate indication justifying continuous prescription could be
identified, and in 12.8%, the indication was uncertain.
Current guidelines recommend peptic ulcer prophylaxis
only for intermediate- to high-risk patients; in the absence
of risk factors, no peptic ulcer prevention is necessary in
patients using NSAID or low-dose acetylsalicylic acid
(ASA) [5, 7]. In addition, there is evidence that concom-
itant use of PPIs might reduce the cardiovascular protection
provided by aspirin [26]. Concerns also exist about the
interaction of PPI and clopidogrel with respect to possible
increases in arteriosclerotic complications [13, 14]. We
therefore rated ulcer prophylaxis in the combination of
aspirin and clopidogrel as an uncertain indication, but it
should be taken into account that the studies reporting these
associations were published after our study sampling
period. Steroids without concomitant NSAID therapy do
not significantly increase the risk of peptic ulcers [27]. No
ulcer prophylaxis is necessary for oral anticoagulation
drugs administered in the therapeutic range to patients
without a history of ulcer/bleeding or concomitant NSAID
treatment [28].
Stress ulcer prophylaxis is recommended only for high
risk-patients in intensive care units (ICU) wards. For these
Table 2 Baseline socio-demographic and clinical characteristics and univariate analysis of the association with inadequate prescription of PPI
Baseline socio-demographic and clinical characteristics (n=681) Values
b Comparison of inadequate with adequate PPI recommendation
(n=594)
c
Age
a, years (±SD) 71 (±14) n.s.
Sex
a
Female 382 (57.0) OR 0.87 (0.6–1.2)
Male 299 (43.0)
Length of stay median, days
a (IQR) 9 (6–14) n.s.
Hospital category
a n.s.
Primary/regional care 214 (31.4)
Secondary dare centres 266 (39.0)
Tertiary care centres 100 (14.7)
Specialty care centres 101 (14.8)
Endoscopy
a 209 (30.7) OR 0.18 (0.12–0.16)
Testing for H. pylori
a 96 (15.0) OR 0.1 (0.06–0.18)
Co-medication
a
None 16 (2.3) OR 0.26 (0.09–0.77)
NSAID 85 (12.5) OR 0.15 ( 0.08–0.25)
Aspirin (low dose) 243 (36.0) OR 1.2 (0.8–1.73)
Coxib 23 (3.4) OR 1.96 (0.71–5.4)
Corticoid 59 (8.7) OR 0.66 (0.38–1.1)
Warfarin/coumadin 54 (7.9) OR 0.4 (0.22–0.69)
Polypharmacy
a (>5 substances) 520 (76.4) OR 1.15 (0.79–1.68)
NSAID, Non-steroidal anti-inflammatory drug; PPI, proton pump inhibitor; SD, standard deviation; IQR, interquartile range; n.s., not significan
aSignificant associations
bUnless stated otherwise, data are given as the number (n) with the percentage in parenthesis
cPatients with indeterminate indication for PPI were excluded. Values are given as the odds ratio (OR) with the 95% confidence interval in parenthesis
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and coagulopathy have been identified as strong indepen-
dent risk factors [29]. The American Society of Health
Service guidelines also denote sepsis and specific illnesses,
such as spinal cord injury, as determining factors for stress
ulcer prophylaxis [30]. Patients from ICU wards were
excluded from our study.
The diagnosis of gastritis is based on histological
examination of the gastric mucosa. Macroscopic signs,
such as erythema or erosion, are of very limited value in the
evaluation of gastritis and H. pylori infection [31, 32]. We
consider the recommendation of continuous PPI therapy
based only on visual findings of macroscopic erythema or
erosion to be inadequate if there were no contraindications
for biopsy and no biopsy was taken.
We assume that low-dose aspirin or NSAIDs in low-risk
patients, steroid therapy or oral anticoagulant treatment may
have been a frequent trigger for inappropriate prescriptions
(Table 3). For more than one third of inappropriate PPI
prescriptions ,we found no explanation.
Doctors may not be aware of existing guidelines and use
PPIs uncritically in good faith as stress ulcer prophylaxis
without indication. Inappropriate assumptions about the
risk of ulcer development during hospitalization may also
be an explanation for the prescribing behaviour. Although
endoscopy, testing for H. pylori and co-medication with
Table 3 Rating of indication, results and categories (n=681)
Rating of indication for PPI Presumed reason for recommendation of continuous prescription of PPIs Number (%)
Adequate documented indication (n=223; 32.8%) NSAID in high-risk patients 90 (40.4)
Gastric or duodenal ulcer 46 (20.6)
GERD 45 (20.2)
Proven gastritis with/ without helicobacter 37 (16.6)
Macroscopic erosion or erythema, no biopsy because of oral
anticoagulation
5 (2.2)
Documented indication uncertain (n=87; 12.8%) Clopidogrel and low dose aspirin 43 (49.4)
Macroscopic gastric erythema or erosion, result outstanding at discharge 13 (15.0)
History of gastritis, no endoscopy, no further information 10 (11.5)
Oesophageal varices 10 (11.5)
Barrett–Oesophagus 5 (5.7)
Dyspepsia 4 (4.6)
Anaemia, no endoscopy 2 (2.3)
No documented adequate indication
(n=371; 54.4%)
No reason for PPI found 140 (37.8)
Low-dose aspirin, no documented history of bleeding 108 (29.1)
Macroscopic gastric erythema or erosion, no biopsy, no H. pylori testing 27 (7.3)
NSAID <65y, no history of bleeding 23 (6.2)
Clopidogrel alone 23 (6.2)
Corticosteroid alone 21 (5.7)
Oral anticoagulation 15 (4.0)
Coxib alone 9 (2.4)
PPI after completed H. pylori-treatment, eradication, no ulcer 3 (0.8)
Corticosteroid and oral anticoagulation 2 (0.5)
GERD. Gastroesophageal reflux disease
PPI type: Pantoprazole Esomeprazole Omeprazole Lansoprazole
n = 487 (71.5%) 116 (17.0%) 77 (11.3%) 1 (0.2%)
No dosage 4 (0.8%) 1 (0.9%) 3 (3.9%)
20 mg 104 (21.3%) 60 (51.7%) 49 (63.6%)
40 mg 312 (64.1%) 47 (40.5%) 20 (26%) 1 (100%)
80 mg 65 (13.4%) 8 (6.9%) 5 (6.5%)
120 mg 2 (0.4%)
Table 4 Recommended PPI/
daily doses
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cantly decreased the risk of inadequate PPI prescribing,
more than half of these patients had no identifiable
indication for PPI prescription. It is notable that 17 patients
in our sample underwent endoscopy and were subsequently
prescribed PPIs, although no pathology was found and no
ulcerogenic medication was administered.
The high rates of inappropriate PPI prescriptions in
hospitals observed in our study are consistent with rates
published from other studies. Two Swedish studies found that
59–81% of hospitalized patients received acid suppression
therapy without appropriate indication [16, 18], while two
Italian studies reported 41.5% [17] and 68%, respectively.
[21] A 1-day survey at an Irish hospital revealed that 30% of
patients were on PPI medication; of these, 71% were started
on PPIs in hospital and 33% had no evidence-based
indication [15]. An American study found that 60% of PPI
treatments started in the hospital had no medical basis [19];
after discharge 46–80% and 50% of these patients were still
on PPIs after 3 and 6 months, respectively [19, 21].
Inappropriate prescribing of PPIs is an important issue
mainly for two reasons. First, the administration of
unnecessary medication leads to polypharmacy and can
lead to side-effects and pharmacological interactions. PPI
use has been found to have a significant association with
community-acquired pneumonia [25]a n dClostridium
difficile-associated diarrhoea [24] Long-term PPI therapy
has been suspected to be associated with an increased risk
of hip fractures [22, 23].
PPIs are a major burden for the national healthcare
budget. It was very noticeable that more than two thirds of
the discharge letters analysed recommended pantoprazole
which, at the time of the study, was much more expensive
than the generic omeprazole. At equipotent doses, different
PPIs are considered to be equally efficient in inhibiting
gastric acid secretion [33, 34]. Hospitals significantly
influence drug prescription behaviour in the primary care
setting [35]. Moreover, in Germany, many hospitals receive
PPIs at no or minimal cost, and manufacturers expect that
continued prescribing in primary care will reimburse them
for this initial “loss” [36]
This is the first study in Germany to assess the
appropriateness of PPI prescribing in hospital discharge
letters. Theoretically, it is possible that the GP practices
participating in our study failed to identify all discharge
letters with a PPI recommendation. However, it is unlikely
that such an omission would have introduced a significant
selection bias. Our assessment of the appropriateness of the
drug recommendation is solely based on information
available in the discharge letter; consequently, the numbers
of inappropriate PPI recommendations may be slightly
overestimated. Nevertheless, discharge letters should pro-
vide sufficient information to allow the GP to understand
the recommendation when specific hospital drugs are to be
continued in the primary care setting.
Hospitals should critically review their practice of recom-
mending PPIs in their discharge letters and clearly document
the reason for continued PPI use after discharge. Likewise,
GPs should carefully assess the need for continuous prescrip-
tion. The reasons why evidence-based clinical guidelines are
obviously not observed merits further research.
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